drugset / Trial / NCT02564198
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Timeline
- Start
- 2015-12-11
- Primary completion
- 2019-07-16
- Completion
- 2019-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 12 mg/kg | Intravenous |